Dear IXA Member,

On behalf of the International Xenotransplantation Association (IXA) we would like to encourage you to participate in our 2021 Election.

To be eligible to vote you must be a Full, Trainee, Emeritus or Honorary member of IXA.

  1. Login into your account
  2. Click the button below and you will be taken to the election ballot.
  3. Prior to accessing the ballot you may view bios and photos on this page.
Deadline to vote:
Sunday May 16, 2021 at 23:59. EDT (Montreal time)

Thank you for being an active member of our Association, and we look forward to sharing the results of our election during our Business Meeting of the IXA/CTRMS Joint Virtual Congress taking place on September 23-25, 2021. Visit for more information. for more information.


Eckhard Wolf
IXA Secretary-Treasurer


President-Elect (Running Unopposed)
Muhammad Mansoor Mohiuddin

Dr. Muhammad Mansoor Mohiuddin is a Professor of Surgery and Director of Cardiac Xenotransplantation Program at the University of Maryland Baltimore, MD, USA. He has previously served as the chief of transplantation of Cardiothoracic Surgery Research Program at National Heart Lung and Blood Institute of NIH and held faculty positions at University of Pennsylvania, Philadelphia and Rush University, Chicago. Dr. Mohiuddin has been involved in xenotransplantation research since 1992 and has started Xenotransplantation research programs at the above institutions. Dr. Mohiuddin received his MBBS (MD) degree from Dow Medical College, Karachi, Pakistan and after completing his preliminary surgical training at Civil Hospital Karachi, finished his fellowships at University of Pennsylvania and Institute of Cellular Therapeutics (Drexel University).

Dr. Mohiuddin has devoted his entire career to xenotransplantation. His contribution to xenotransplantation includes demonstration of longest survival of heterotopic and now orthotopic cardiac xenograft (submitted). He served as Councilor of IXA for 4 years where he was instrumental in promoting liaisonship between IXA and FDA. He has published over 100 papers, over 150 abstracts and has delivered numerous presentations on xenotransplantation.

Dr. Mohiuddin is an Associate Editor of Journal Transplantation and reviews manuscripts for many other journals. He is also President-Elect of Dow Graduate Association of North America. His accomplishments include several NIH and non-NIH grants during his academic career.

Secretary-Treasurer (Running Unopposed)
Rita Bottino

Dr. Bottino is a world-renowned expert in pancreas and islet cell biology and transplantation. She served as the Director of the Islet Isolation Laboratory, first, at the University of Pittsburgh and, subsequently, at Allegheny Health Network. In conjunction with the Cleveland Clinic, her lab pioneered the utility of remote clinical islet isolation as part of total pancreatectomy and autologous islet transplantation. As the Director of the core, she has prioritized the ability to function as a Core Resource to assist investigators by providing the specialized or rare islets they require for their studies. The Bottino Lab has an unmatched record of islet isolations from pancreatic organs obtained from deceased human donors of all ages, including newborn.

Dr. Bottino has an extensive expertise in the isolation of islet cells from pigs, monkeys and rodents for research purposes, for experimental transplantation, as well as in developing models of diabetes in animals, in particular monkeys. Dr. Bottino conducted pioneer studies on the use of genetically engineered pigs as islet donors for xenotransplantation in immunosuppressed diabetic nonhuman recipients, demonstrating long-term normalization of blood glucose levels in recipients. Dr. Bottino currently serves as a Councilor of the IXA from North America. She has published >150 peer-reviewed articles in high impact journals, including Nature Medicine, Nature Communication, Lancet, Cell, Cell Rep, J Clin Invest, JCI Insight, Gastroenterology, and many more.

Councilor ASIA (Running Unopposed)
Ik Jin Yun
Ik Jin Yun has been a transplant surgeon since 1996, majoring in kidney and liver transplantation and has performed more than 200 cases of kidney and 100 cases of liver transplantation. He has always been interested in and studied xeno-organ transplantation since becoming a transplantation surgeon. Since 2011, he has received national funds for xeno-organ transplantation and on-going experiments for the pig to NHP organ transplantation. His team has possessed the top survival records for the kidney, heart and partial cornea pig to NHP xeno-organ transplantation in Korea. He is a member of IXA and has participated in all the IXA Congresses since 2011. Dr. Yun has been elected President of the Korean Xenotransplantation Association (KXA) and is preparing to start the Presidential work in June. Korea is one of the most active countries in xenotransplantation research. Representing this society of xenotransplantation of Korea, he has worked hard to expand xeno-organ transplantation. He plans to devote his best work to keep studying xeno-organ transplantation experiments until establishing the clinical xenotransplantation in the human. It is expected that he will work towards increasing collaborations between IXA and KXA if he is appointed as councilor of IXA.
Councilor Europe (one position)
Paolo Brenner

Prof. Paolo Brenner is a Professor for Cardiac Surgery and Head of the Cardiac Xenotransplantation Program of the Dept. of Cardiac Surgery of the Ludwig-Maximilians-University (LMU) in Munich, Germany. Finishing his doctorate dealing with the mechanism of action of ACE-Inhibitors in 1995, Dr. Brenner was co-inventor of Ramipril. Since 1997 he established xenogeneic heart transplantation in Munich during a PhD-fellowship in the Walter-Brendel-Centre. He habilitated 2004 with the thesis of xenoperfusion and orthotopic or heterotopic xenotransplantation of hDAF-pig-hearts. In 2011, he qualified as an APL Professor in the Medical Department of the LMU.Prof. Brenner has received various grants for xenotransplantation such as: 1996-2004 from the Bavarian-Research-Foundation, 2004-2012 as DFG-Research-Group FOR535, 2012-2024 from the DFG-transregio-SFB127. Between 2017 -2020 Prof. Brenner achieved the worldwide first successful long-term surviving series in orthotopic cardiac xenotransplantation published in Nature and ISHLT Journal. He is member of several Cardiothoracic and Transplantation Societies.

The pioneer work of Prof. Brenner was honored by international and national awards like the Young-Investigator´s-Award of the EACTS in 1998, the Biotest-Award of ESOT in 1999, the Rolf-Becker-Prize of the LMU in 1999, the Scientific Award of the TTS-IXA in 2019 and the Ernst-Derra-Award of the DGTHG in 2020. Now he is planning a first clinical trial for cardiac xenotransplantation.

Bjorn Petersen

Dr. Björn Petersen studied Veterinary Medicine at the Veterinary University in Hannover, from which he graduated in 2002. The same year, he started his doctoral thesis at the Institute of Farm Animals in Mariensee, Germany, under the supervision of Prof. Heiner Niemann. Together with a colleague, he established the first pig cloning protocol in continental Europe and published the generation of GGTA1-KO pigs by somatic cell nuclear transfer and homologous recombination in 2004. Since 2002, Dr. Petersen has continuously worked in the xenotransplantation field and pioneered genome editing in pigs by employing ZFNs to generate biallelic GGTA1-KO pigs in 2011. He is a worldwide reputed scientist in the pig genome editing and Xenotransplantation field, where he developed essential pig models bringing xenotransplantation closer to the clinics.

Councilor USA (Running Unopposed)
Jay A. Fishman
Jay A. Fishman, M.D. is Professor of Medicine at Harvard Medical School, Director of the Transplant Infectious Diseases and Compromised Host Program at Massachusetts General Hospital (MGH), and Associate Director of the MGH Transplant Center. Dr. Fishman attended Johns Hopkins University School of Medicine, completed Internal Medicine and Infectious Disease training and Fellowships in Molecular Biology and Genetics at MGH and Harvard Medical School. Dr. Fishman established the Transplant and Immunocompromised Host Program training many leaders in this field worldwide. His experience in infectious diseases of solid organ and stem cell transplant recipients and background in immunology, virology and molecular biology provide the basis of studies of infectious risk in xenotransplantation, notably of viruses, including porcine endogenous retrovirus and cytomegalovirus, in preclinical models of xenotransplantation. Dr. Fishman has contributed to IXA guidelines for clinical xenotransplantation and is chair of the Infectious Disease Committee of IXA. He has over 300 peer-reviewed publications and a frequent contributor at international symposia. He is Past-President of the American Society of Transplantation. He is a Fellow of the American College of Physicians, the American Society of Transplantation, and the Infectious Disease Society of America. He has received career achievement awards from AST and TTS.



Staff Directory


The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7